Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Fatty acids are an important source of energy and adenosine triphosphate (ATP) for many cellular organisms. Excess fatty acids, glucose, and other nutrients can be stored efficiently as fat. Triglycerides yield more than twice as much energy for the same mass as do carbohydrates or proteins. All cell membranes are built up of phospholipids, each of which contains two fatty acids. Fatty acids are also used for protein modification. The metabolism of fatty acids, therefore, consists of catabolic processes that generate energy and primary metabolites from fatty acids, and anabolic processes that create biologically important molecules from fatty acids and other dietary carbon sources.
- Lipolysis is carried out by lipases.
- Once freed from glycerol, free fatty acids can enter blood and muscle fiber by diffusion.
- Beta oxidation splits long carbon chains of the fatty acid into acetyl CoA, which can eventually enter the TCA cycle.
Briefly, β-oxidation or lipolysis of free fatty acids is as follows:
- Dehydrogenation by acyl-CoA dehydrogenase, yielding 1 FADH2
- Hydration by enoyl-CoA hydratase
- Dehydrogenation by 3-hydroxyacyl-CoA dehydrogenase, yielding 1 NADH
- Cleavage by thiolase, yielding 1 acetyl-CoA and a fatty acid that has now been shortened by 2 carbons (acyl-CoA)
This cycle repeats until the FFA has been completely reduced to acetyl-CoA or, in the case of fatty acids with odd numbers of carbon atoms, acetyl-CoA and 1 mol of propionyl-CoA per mol of fatty acid.
Fatty acids as an energy source
Fatty acids, stored as triglycerides in an organism, are an important source of energy because they are both reduced and anhydrous. The energy yield from a gram of fatty acids is approximately 9 Kcal (37 kJ), compared to 4 Kcal/g (17 kJ/g) for carbohydrates. Since the hydrocarbon portion of fatty acids is hydrophobic, these molecules can be stored in a relatively anhydrous (water-free) environment. Carbohydrates, on the other hand, are more highly hydrated. For example, 1 g of glycogen can bind approximately 2 g of water, which translates to 1.33 Kcal/g (4 Kcal/3 g). This means that fatty acids can hold more than six times the amount of energy per unit of storage mass. Put another way, if the human body relied on carbohydrates to store energy, then a person would need to carry 67.5 lb (31 kg) of hydrated glycogen to have the energy equivalent to 10 lb (5 kg) of fat. Hibernating animals provide a good example for utilizing fat reserves as fuel. For example, bears hibernate for about 7 months, and, during this entire period, the energy is derived from degradation of fat stores.
Digestion and transport
Fatty acids are usually ingested as triglycerides, which cannot be absorbed by the intestine. They are broken down into free fatty acids and monoglycerides by pancreatic lipase, which forms a 1:1 complex with a protein called colipase, which is necessary for its activity. The activated complex can work only at a water-fat interface. Therefore, it is essential that fatty acids (FA) be emulsified by bile salts for optimal activity of these enzymes.
The digestion products of triglycerides are absorbed primarily as free fatty acids and 2-monoglycerides, but a small fraction are absorbed as free glycerol and as diglycerides. Once across the intestinal barrier, they are reformed into triglycerides and packaged into chylomicrons or liposomes, which are released into the lacteals, the capillaries of the lymph system and then into the blood. Eventually, they bind to the membranes of hepatocytes, adipocytes or muscle fibers, where they are either stored or oxidized for energy. The liver acts as a major organ for fatty acid treatment, processing chylomicron remnants and liposomes into the various lipoprotein forms, in particular VLDL and LDL. Fatty acids synthesized by the liver are converted to triglyceride and transported to the blood as VLDL. In peripheral tissues, lipoprotein lipase digests part of the VLDL into LDL and free fatty acids, which are taken up for metabolism. This is done by the removal of the triglycerides contained in the VLDL. What is left of the VLDL absorbs cholesterol from other circulating lipoproteins, becoming LDLs. LDL is absorbed via LDL receptors. This provides a mechanism for absorption of LDL into the cell, and for its conversion into free fatty acids, cholesterol, and other components of LDL. The liver controls the concentration of cholesterol in the blood by removing LDL. Another type of lipoprotein known as high-density lipoprotein, or HDL collects cholesterol, glycerol and fatty acids from the blood and transports them to the liver. In summary:
- Chylomicrons carry diet-derived lipids to body cells
- VLDLs carry lipids synthesized by the liver to body cells
- LDLs carry cholesterol around the body
- HDLs carry cholesterol from the body back to the liver for breakdown and excretion.
When blood sugar is low, glucagon signals the adipocytes to activate hormone-sensitive lipase, and to convert triglycerides into free fatty acids. These have very low solubility in the blood, typically about 1 μM. However, the most abundant protein in blood, serum albumin, binds free fatty acids, increasing their effective solubility to ~ 1 mM. Thus, serum albumin transports fatty acids to organs such as muscle and liver for oxidation when blood sugar is low.
Transport and oxidation
- Main article: Fatty acid degradation
The neutral lipids stored in adipocytes (and in steroid synthesizing cells of the adrenal cortex, ovary, and testes) in the form of lipid droplets, with a core of sterol esters and triacylglycerols surrounded by a monolayer of phospholipids, are coated with perilipin, a protein that acts as a protective coating from the body’s natural lipases, such as hormone-sensitive lipase,. However, when hormones such as epinepherine or glucagon are secreted in response to low levels of glucose, this triggers an intracellular secondary messenger cascade that phosphorylates hormone-sensitive lipase to break triglycerides into glycerol and free fatty acids for use in metabolism, a process called lipolysis.
The free fatty acids move into the blood stream where they are bound by serum albumin and transported to the tissue needing fuel. Once the fatty acids reach the target tissue, they are released by serum albumin and cross into the cytosol. The enzymes used in fatty acid oxidation in animal cells are located in the mitochondrial matrix (as was demonstrated by Eugene P. Kennedy and Albert Lehninger in 1948). Free fatty acid chains of more than 12 carbons require the help of membrane transporters to cross into the membrane into the mitochondria, where they undergo Fatty acid degradation.
Fatty acid degradation is the process in which fatty acids are broken down, resulting in release of energy. It includes three major steps:
Fatty acids are transported across the outer mitochondrial membrane by carnitine-palmitoyl transferase I (CPT-I), and then couriered across the inner mitochondrial membrane by carnitine. Once inside the mitochondrial matrix, the fatty acyl-carnitine (such as palmitoylcarnitine) reacts with coenzyme A to release the fatty acid and produce acetyl-CoA. CPT-I is believed to be the rate-limiting step in fatty acid oxidation.
Once inside the mitochondrial matrix, fatty acids undergo β-oxidation. During this process, two-carbon molecules acetyl-CoA are repeatedly cleaved from the fatty acid. Acetyl-CoA can then enter the citric acid cycle, which produces NADH and FADH2. NADH and FADH2 are subsequently used in the electron transport chain to produce ATP, the energy currency of the cell.
Besides β-oxidation, other oxidative pathways are sometimes employed. α-Oxidation is used for branched fatty acids that cannot directly undergo β-oxidation. The smooth ER of the liver can perform ω-oxidation, which is primarily for detoxification but can become much more prevalent in cases of defective β-oxidation. Fatty acids with very long chains (20 or more carbons) are first broken down to a manageable size in peroxisomes.
Regulation and control
It has long been held that hormone-sensitive lipase (HSL) is the enzyme that hydrolyses triacylglycerides to free fatty acids from fats (lipolysis). However, more recently it has been shown that at most HSL converts triacylglycerides to monoglycerides and free fatty acids. Monoglycerides are hydrolyzed by monoglyceride lipase; adipose triglyceride lipase may have a special role in converting triacylglycerides to diacylglycerides, while diacylglycerides are the best substrate for HSL. HSL is regulated by the hormones insulin, glucagon, norepinephrine, and epinephrine.
Glucagon is associated with low blood glucose, and epinephrine is associated with increased metabolic demands. In both situations, energy is needed, and the oxidation of fatty acids is increased to meet that need. Glucagon, norepinephrine, and epinephrine bind to G protein-coupled receptors that activate adenylate cyclase to produce cyclic AMP. As a consequence, cAMP activates protein kinase A, which phosphorylates (and activates) hormone-sensitive lipase.
When blood glucose is high, lipolysis is inhibited by insulin. Insulin activates protein phosphatase 2A, which dephosphorylates HSL, thereby inhibiting its activity. Insulin also activates the enzyme phosphodiesterase, which breaks down cAMP and stops the re-phosphorylation effects of protein kinase A.
For the regulation and control of metabolic reactions involving fat synthesis, see lipogenesis.
Disorders of fatty acid metabolism can be described in terms of, for example, hypertriglyceridemia (too high level of triglycerides), or other types of hyperlipidemia. These may be familial or acquired.
Familial types of disorders of fatty acid metabolism are generally classified as inborn errors of lipid metabolism. These disorders may be described as fatty oxidation disorders or as a lipid storage disorders, and are any one of several inborn errors of metabolism that result from enzyme defects affecting the ability of the body to oxidize fatty acids in order to produce energy within muscles, liver, and other cell types.
- ↑ Wong K. Making Fat-proof Mice. Scientific American. URL accessed on 2009-05-22.
- ↑ De Vivo, D. C. et al. (1998) L-Carnitine Supplementation in Childhood Epilepsy: Current Perspectives. Epilepsia. Vol. 39(11), p.1216-1225. 
- ↑ Zechner R., Strauss J.G., Haemmerle G., Lass A., Zimmermann R. (2005) Lipolysis: pathway under construction. Curr. Opin. Lipidol. 16, 333-340.
Berg, J.M., et al., Biochemistry. 5th ed. 2002, New York: W.H. Freeman. 1 v. (various pagings).
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|